Zejula (niraparib) / GSK, J&J 
Welcome,         Profile    Billing    Logout  
 46 Diseases   163 Trials   163 Trials   3638 News 
208 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zejula (niraparib) / GSK, J&J
DIDO, NCT04983745: Niraparib and Dostarlimab in HRD Solid Tumors

Recruiting
2
30
US
Combination drug
West Cancer Center
Homologous Recombination Deficient Solid Tumors
08/24
08/25
ANALLISA, NCT06180356: Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Not yet recruiting
2
30
NA
Niraparib oral tablets
MedSIR
Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
10/25
11/25
NCT04493060: Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Active, not recruiting
2
22
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Niraparib, MK-4827, MK4827
Mayo Clinic, National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/23
09/24
PALB2-PARPi-01, NCT05232006: PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

Not yet recruiting
2
12
NA
Niraparib
Assistance Publique - Hôpitaux de Paris
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
09/24
05/30
NCT05689021: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Recruiting
2
30
US
Abiraterone Acetate/Niraparib, Abiraterone Acetate and Niraparib Tosylate Monohydrate, Abiraterone Acetate/Niraparib Tosylate Monohydrate, Akeega, CJNJ-67652000, Niraparib and Abiraterone Acetate, Niraparib Tosylate Monohydrate and Abiraterone Acetate, Niraparib Tosylate Monohydrate/Abiraterone Acetate, Niraparib/Abiraterone Acetate, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
09/24
09/25
NIPAVect, NCT03983993: Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting
2
40
US
Niraparib, MK-4827, Zejula, Panitumumab, ABX-EGF, Vectibix
Emory University, GlaxoSmithKline, National Institutes of Health (NIH), National Cancer Institute (NCI)
Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable, RAS Wild Type, Stage IV Colorectal Cancer AJCC v8, MSI-H Colorectal Cancer
10/24
10/24
NCT05126342: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Not yet recruiting
2
100
NA
Niraparib, Zejula, Dostarlimab, TSR-042
AGO Research GmbH, GlaxoSmithKline
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
11/24
11/26
NCT04992013: Niraparib in Tumors Metastatic to the CNS

Recruiting
2
20
US
Niraparib, Zejula
Massachusetts General Hospital, GlaxoSmithKline
Metastatic Cancer, Central Nervous System Cancer
12/24
12/26
HARMONY, NCT06392841: Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Not yet recruiting
2
64
NA
Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Akeega, Abiraterone Acetate, Zytiga, Prednisone, Rayos, Deltasone, Prednisone Intensol, Docetaxel, Docefrez, Taxotere
Qian Qin, UT Southwestern Comprehensive Cancer Center, Janssen, LP
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
04/27
04/28
ChiCTR2100046269: A phase II trial of combination of niraparib and anlotinib in patients with recurrent small cell lung cancer (SCLC)

Recruiting
2
62
 
Niraparib in combination with Anlotinib
Jilin Provice Cancer Hospital; Jilin Provice Cancer Hospital, Zaiding pharmaceutical (Shanghai) Co. , Ltd.
small cell lung cancer(SCLC)
 
 
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma

Active, not recruiting
2
88
Europe
Niraparib Oral Product, Zejula, Active Symptom Control
University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation
Mesothelioma, Malignant
12/24
12/24
NCT05461690: Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Not yet recruiting
2
50
NA
Niraparib, Zejula
Zhejiang Cancer Hospital, Sun Yat-sen University, Hunan Cancer Hospital, Fujian Cancer Hospital, Zhejiang University, Taizhou Hospital of Zhejiang Province
Homologous Recombination Deficiency, Triple Negative Breast Cancer
12/24
06/25
NCT05870761: Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
35
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Dostarlimab, ANB011, Dostarlimab-gxly, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, Jemperli, TSR 042, TSR-042, TSR042, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Niraparib, MK-4827, MK4827
Casey Cosgrove
Recurrent Endometrial Serous Adenocarcinoma
12/24
12/24
NCI-2021-12582, NCT05174455: Niraparib for the Treatment of Leiomyosarcoma

Withdrawn
2
22
NA
Niraparib Tosylate Monohydrate, Zejula
David Liebner, MD
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Retroperitoneal Sarcoma AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IV Retroperitoneal Sarcoma AJCC v8, Unresectable Leiomyosarcoma
12/24
12/25
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Recruiting
2
44
Europe
Niraparib
ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited
SCLC,Extensive Stage, SLFN11-positive
05/25
10/25
NCT04701307: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Active, not recruiting
2
48
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
05/25
05/25
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
NCT03983226: Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Recruiting
2
167
RoW
Surgery, secondary cytoreduction, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., third-line therapy, Niraparib, maintenance therapy
Shanghai Gynecologic Oncology Group, Fudan University, Shanghai Jiao Tong University School of Medicine, Zhejiang Cancer Hospital, Sun Yat-sen University
Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
06/25
12/26
OU-SCC-PI-4G, NCT05297864: PARP Inhibition for Gliomas (PI-4G or π4g)

Terminated
2
15
US
Niraparib
University of Oklahoma, GlaxoSmithKline
Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
11/23
02/24
NCT05065021: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Recruiting
2
40
Canada
Niraparib, ZEJULA, Dostarlimab, Bevacizumab, Paclitaxel
University Health Network, Toronto, GlaxoSmithKline
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
06/25
06/25
NCT06036966: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Not yet recruiting
2
34
NA
Hetrombopag
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thrombocytopenia
07/25
07/25
NCT05700721: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Recruiting
2
120
US
Niraparib, MK-4827, Dostarlimab
M.D. Anderson Cancer Center
Brain Metastases
08/25
08/27
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
10/25
10/26
NCT05961124: Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Recruiting
2
40
Canada
Niraparib, Zejula
Sunnybrook Health Sciences Centre, GlaxoSmithKline
Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma
09/25
09/27
N-Plus, NCT05460000: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Not yet recruiting
2
640
NA
3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
05/27
05/32
NCT04641247: A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Active, not recruiting
2
26
Europe, Canada, US, RoW
Niraparib
GlaxoSmithKline
Ovarian Neoplasms, Breast Neoplasms
11/25
11/25
NCT04221503: Niraparib/TTFields in GBM

Active, not recruiting
2
30
US
Niraparib, ZEJULA, Optune, Tumor Treatment Fields (TTFields), Planned surgical resection, Tumor Resection
University of Pennsylvania, Tesaro, Inc., NovoCure Ltd.
Glioblastoma, Recurrent Glioblastoma, GBM
12/25
12/25
NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
ARID1A, NCT05523440: Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With Mutation

Recruiting
2
92
US
Bevacizumab, Avastin, Niraparib, Zejula
University of Oklahoma, GlaxoSmithKline
Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
01/26
01/27
PARPi-PANC, NCT05442749: Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer

Recruiting
2
28
Europe
Niraparib
Centre Leon Berard, GlaxoSmithKline
Metastatic Pancreatic Cancer
01/26
09/26
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting
2
315
Canada, US
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab
University of British Columbia, Janssen Inc., University Health Network, Toronto
Prostate Cancer
04/26
04/26
NCT04947254: Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Recruiting
2
200
US
Abiraterone Acetate, CB7630, Zytiga, Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Androgen Deprivation Therapy (ADT), Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Biopsy, BIOPSY_TYPE, Bx, Niraparib, MK-4827, MK4827, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
06/26
06/26
NCT05515575: A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Active, not recruiting
2
8
US
Niraparib
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Sarcoma,Soft Tissue, Sarcoma Uterus
08/26
08/26
NCT05200260: Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Not yet recruiting
2
207
RoW
Primary debulking surgery, PDS, Neoadjuvant chemotherapy, Neoadjuvant chemotherapy followed by interval debulking surgery, NACT-IDS, PARP inhibitor, Niraparib
Shanghai Gynecologic Oncology Group, Fudan University
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
02/27
02/27
SOPRANO, NCT05990192: SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Recruiting
2
42
Europe
Niraparib oral capsule, Zejula, SBRT, Stereotactic Body Radiotherapy
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Ovarian Cancer Recurrent
06/27
06/27
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
NCT05601440: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
2
484
Canada
RP-6306, Gemcitabine, Observation, Niraparib, Fulvestrant
Canadian Cancer Trials Group
Breast Cancer
12/27
06/28
IMPRESS-Norway, NCT04817956: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Hourglass Oct 2019 - Dec 2019 : Proof-of-concept data from OPAL trial in combination with dostarlimab and Avastin for 2L+ PROC ovarian cancer
Recruiting
1b/2
125
Europe, Canada, US
Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel
Tesaro, Inc.
Ovarian Neoplasms
08/24
03/26
ATTACC, NCT04972110: Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

Recruiting
1b/2
196
US
RP-3500 (camonsertib), niraparib, olaparib
Repare Therapeutics, Roche Pharma AG
Advanced Solid Tumor, Adult
03/25
12/25
CAPRICE, NCT05519670: A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

Not yet recruiting
1b/2
72
NA
Niraparib Oral Product
Institut Paoli-Calmettes, GlaxoSmithKline
Breast Cancer
09/27
12/27
2014-004269-26: Niraparib alone or Niraparib and bevacizumab combination in Women with ovarian cancer.

Ongoing
1/2
132
Europe
Niraparib, AVASTIN, MK-4827, Capsule, Solution for infusion, AVASTIN 25 mg/ml Concentrate for solution for infusion
Nordic Society of Gynaecological Oncology - Clinical Trial Unit, Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU), Nordic Society of Gynaecological Oncology (NSGO), TESARO, NSGO
Women with relapsed platinum-sensitive epithelial ovarian cancer, women with relapsed ovarian cancer, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
2017-004927-56: A Phase 1b/2 Trial of SRA737 in Combination with Niraparib in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)

Not yet recruiting
1/2
70
Europe
SRA737 capsules, Niraparib, SRA737, Capsule
Sierra Oncology, Inc., Sierra Oncology, Inc.
Histologically or cytologically confirmed adenocarcinoma of the prostate, Patients with metastatic castration-resistant prostate cancer, Diseases [C] - Cancer [C04]
 
 
2020-000825-18: Safety and efficacy study to evaluate AsiDNA in addition with Niraparib for treatment of relapsed platinum sensitive ovarian cancer already treated with Niraparib since at least 6 months

Ongoing
1/2
26
Europe
AsiDNA, Powder for solution for infusion
Gustave Roussy, Onxeo S.A.
Relapsed platinum sensitive ovarian cancer, Relapsed platinum sensitive ovarian cancer, Diseases [C] - Cancer [C04]
 
 
QUEST, NCT03431350 / 2017-003552-23: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
136
Europe, Canada, US, RoW
Niraparib 200 mg, Cetrelimab 240 mg, JNJ-63723283, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
08/21
12/24
Parpvax, NCT03404960: Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

Checkmark Data from PARPVAX trial in combination with Opdivo / Yervoy in advanced pancreatic cancer
Aug 2022 - Aug 2022: Data from PARPVAX trial in combination with Opdivo / Yervoy in advanced pancreatic cancer
Active, not recruiting
1/2
104
US
Niraparib + Nivolumab, Arm A, Niraparib + Ipilimumab, Arm B
University of Pennsylvania, Bristol-Myers Squibb, GlaxoSmithKline
Pancreatic Adenocarcinoma
04/22
06/26
NCT03221400: PEN-866 in Patients With Advanced Solid Malignancies

Recruiting
1/2
340
US
PEN-866 Sodium, fluorouracil, 5-Fluorouracil, 5-FU, Folinic acid, Leucovorin, Niraparib, Zejula
Tarveda Therapeutics
Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
01/23
06/23
2023-000183-65: Niraparib and Dostarlimab plus (Chemo)RadIotherapy in head and Neck squamous cell carcinoma niraparib y dostarlimab más (quimio)radioterapia en carcinoma de células escamosas de cabeza y cuello

Not yet recruiting
1/2
34
Europe
Niraparib, Dostarlimab, Tablet, Concentrate for solution for infusion
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC), GSK
Locally-Advanced head and Neck squamous cell carcinoma Carcinoma de células escamosas de cabeza y cuello localmente avanzado, Head and Neck squamous cell carcinoma Carcinoma de células escamosas de cabeza y cuello, Diseases [C] - Cancer [C04]
 
 
REVOCAN, NCT04826198: Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Recruiting
1/2
26
Europe
AsiDNA, Niraparib, Olaparib, Rucaparib
Gustave Roussy, Cancer Campus, Grand Paris
Ovarian Cancer
10/23
10/23
ZN-c3-006, NCT05198804: A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Active, not recruiting
1/2
117
Europe, US
ZN-c3, Niraparib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
05/25
05/25
TRIO-US L-06 , NCT03830918: Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Recruiting
1/2
74
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Niraparib, MK-4827, MK4827, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Tesaro, Inc.
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/25
01/26
ONC-2022-001, NCT06258018: Niraparib and Temozolomide in Patients Glioblastoma

Not yet recruiting
1/2
86
Europe
Temodal, Temozolomide, Niraparib
Armando Santoro, MD, Istituto Clinico Humanitas, GlaxoSmithKline
Glioma, Malignant
12/26
09/27
NICARAGUA, NCT03425201 / 2017-004367-12: Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer

Active, not recruiting
1/2
20
Europe
Niraparib plus Cabozantinib
Fundacion CRIS de Investigación para Vencer el Cáncer, Ipsen, GlaxoSmithKline, Apices Soluciones S.L.
Urothelial Cancer
04/24
04/24
LUNAAR, NCT06329830: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Not yet recruiting
1/2
30
US
177Lu-PSMA-617, Pluvicto, Niraparib abiraterone acetate, Akeega, Prednisone, Rayos, Prednisone Intensol, Deltasone
Rohan Garje, Janssen Scientific Affairs, LLC
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
07/26
07/28
TBCRC 050, NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Recruiting
1/2
40
US
Niraparib, formerly MK-4827, Trastuzumab
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Tesaro, Inc., Susan G. Komen Breast Cancer Foundation, Breast Cancer Research Foundation of Alabama, VFoundation
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
11/24
12/24
MORPHEUS mUC, NCT03869190 / 2017-004634-28: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hourglass Jul 2020 - Dec 2020 : Initial safety and efficacy data from P1b/2 MORPHEUS trial for bladder cancer
Recruiting
1/2
645
Europe, US, RoW
Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
Hoffmann-La Roche, Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
Urothelial Carcinoma, Bladder Cancer
12/24
11/27
TOPAZ, NCT04926324: A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Recruiting
1/2
38
US
Niraparib, Zejula, Dostarlimab, Jemperli, Short course radiation, IMRT, VMAT
Joseph Caster, Ph.D., M.D., GlaxoSmithKline
Rectal Neoplasms, Rectal Neoplasm Malignant
12/24
12/26
NCT05672095: Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Not yet recruiting
1/2
45
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Niraparib, MK-4827, MK4827, Questionnaire Administration, Selenium, Se
City of Hope Medical Center, National Cancer Institute (NCI)
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
11/26
11/26
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
NCT05898399: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Recruiting
1/2
240
US
ART6043, Olaparib, Niraparib
Artios Pharma Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
05/26
12/26
ASCLEPIuS, NCT04194554: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Recruiting
1/2
100
US
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT), Ultra-hypofractionated radiotherapy
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Prostate Cancer
11/26
05/27
RADIAN, NCT05784012: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
34
Europe
Dostarlimab, Niraparib, cisplatin plus radiotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, GlaxoSmithKline, MFAR
Head and Neck Squamous Cell Carcinoma
09/27
03/29
NCT03307785: Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Active, not recruiting
1
58
US
Niraparib, Zejula, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, Avastin, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Tesaro, Inc.
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
02/20
08/24
ChiCTR1900024488: A phase 1b study for cisplatin in combination with niraparib and sintilimab in the treatment of patients with advanced solid cancer

Recruiting
1
30
 
cisplatin, niraparib, sintilimab
Chinese PLA General Hospital; Chinese PLA General Hospital, funds for scientific research
solid cancer
 
 
NCT04577833: A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Active, not recruiting
1
136
Europe, US, RoW
Niraparib, Abiraterone Acetate (AA), Prednisone
Janssen Research & Development, LLC
Prostatic Neoplasms
10/21
12/25
NCT04764084: Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Not yet recruiting
1
52
RoW
Niraparib, Zejula, Anlotinib
Beijing Cancer Hospital
HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer
11/21
02/23
TABLET, NCT03329001: Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Completed
1
236
US
Niraparib Tablet, Niraparib Capsule
Tesaro, Inc.
Neoplasms
12/21
06/23
NCT03891615: Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Recruiting
1
30
US
Niraparib, ZEJULA, Osimertinib, Tagrisso
Massachusetts General Hospital, Tesaro, Inc.
Lung Cancer
04/22
04/24
NCT03945721: A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

Recruiting
1
20
US
Niraparib, Radiation Therapy
Massachusetts General Hospital, Tesaro, Inc.
Triple Negative Breast Cancer, Residual Disease
05/22
12/26
NCT04235101: Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Completed
1
32
Europe
SYD985 + Niraparib, (vic-)trastuzumab duocarmazine + Zejula
Byondis B.V.
Solid Tumor
04/23
04/23
NCT03154281: Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Active, not recruiting
1
24
US
niraparib, MK-4827, everolimus, Afinitor
Avera McKennan Hospital & University Health Center
Breast Cancer, Ovarian Cancer
06/23
06/24
ChiCTR2200063037: An open-label, single-arm, phase Ib trial of combination of niraparib and radiotherapy in the immunomaintenance phase for newly diagnosed unresectable locally advanced or distant metastatic esophageal squamous cell carcinoma

Not yet recruiting
1
12
 
Nilaparib: 200 mg oral QD from the day of initiation of radiotherapy to the day after completion of radiotherapy; Radiotherapy: At least 1 tumor suitable for biopsy was selected to undergo SBRT, 4-8 Gy/day, 3-5 times in total; (During the maintenance phase of immunotherapy and within 8 weeks after compl
Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital Affiliated to Shandong University, Research project funds
esophageal squamous cell carcinoma
 
 
NCT03695380: A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Completed
1
77
Europe, US
Cobimetinib, Niraparib, Atezolizumab
Hoffmann-La Roche
OVARIAN CANCER
07/23
07/23
NCT05261269: A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Completed
1
30
US
DAN-222, Niraparib
Dantari, Inc.
HER2-negative Metastatic Breast Cancer
09/23
10/23
NCT05076513: Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

Recruiting
1
42
US
Niraparib, Zejula, Radiation therapy
Nader Sanai, Barrow Neurological Institute, Ivy Brain Tumor Center, University of California, San Francisco, GlaxoSmithKline
Glioblastoma, Glioblastoma Multiforme, Glioma, GBM, Glioma, Malignant, Glioblastoma Multiforme of Brain
08/24
02/25
NCT04267939: ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Terminated
1
14
US
Elimusertib (BAY1895344), Niraparib
Bayer, GlaxoSmithKline
Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
12/23
12/23
NCT03586661: Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
1
31
US
Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Progressive Disease, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
12/26
12/26
NCT06161493: ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Recruiting
1
26
US
ZEN003694, Niraparib, MK-4827, Zejula
Haider Mahdi, GlaxoSmithKline, Zenith Epigenetics
Ovarian Cancer, Recurrent Solid Tumors
12/26
12/29
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
204
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/25
01/25
NCT04149145: Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

Withdrawn
1
40
NA
M4344+Niraparib, PARPi+ATRi
University of Alabama at Birmingham
Ovarian Cancer Recurrent
05/24
05/27
iNNOVATE, NCT04502602: Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

Recruiting
1
45
US
Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg, Niraparib 100 mg, Niraparib 200 mg, Niraparib 300 mg, Niraparib at RP2D, Neratinib at RP2D
Virginia Commonwealth University, Puma Biotechnology, Inc., GlaxoSmithKline
Advanced Solid Tumor, Ovarian Cancer
05/24
05/29
NCT04481113: Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Active, not recruiting
1
8
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Niraparib Tosylate Monohydrate, Zejula
OHSU Knight Cancer Institute, Eli Lilly and Company, GlaxoSmithKline, Oregon Health and Science University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
06/24
12/25
RiNG, NCT05666349: Reirradiation and Niraparib in Patients With Recurrent Glioblastoma

Withdrawn
1
15
NA
Niraparib, Zejula, Re-irradiation (re-RT)
University College, London, GlaxoSmithKline
Recurrent Glioblastoma
10/23
10/23
NCT04673448: Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
1
18
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Dostarlimab-gxly, Jemperli, Niraparib, MK-4827, MK4827
University of Washington, GlaxoSmithKline
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA-Associated Ovarian Carcinoma, Metastatic BRCA-Associated Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
09/24
03/26
NIREC, NCT05289648: Niraparib in High-grade Endometrial Cancer Trial

Not yet recruiting
1
31
NA
Niraparib oral capsule, Zejula
Sir Mortimer B. Davis - Jewish General Hospital
Endometrial Cancer, Serous Adenocarcinoma, Uterine Neoplasm
10/25
01/26
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/25
08/25
NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Terminated
1
23
US
Niraparib, MK-4827, Carboplatin, Paraplatin
Georgetown University, Tesaro, Inc., Oregon Health and Science University
Solid Tumor, Adult, Homologous Recombination Deficiency
10/23
10/23
NCT05406700: Niraparib In Recurrent IDH 1/2 Gliomas

Recruiting
1
16
US
Niraparib, Zejula, Resection/Treatment with Niraparib
Massachusetts General Hospital, GlaxoSmithKline
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
08/25
02/26
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
NCT05694715: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting
1
24
US
Niraparib, Zejula, Small molecule inhibitor, Irinotecan, Camptosar, Irinotecan hydrochloride, CPT-11
University of California, San Francisco, GlaxoSmithKline
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
01/28
01/28
SCOOP, NCT04544995 / 2020-002359-39: Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors

Suspended
1
116
Europe, RoW
Niraparib, Dostarlimab
GlaxoSmithKline
Neoplasms
09/28
04/29
ArteRIB, NCT04774406: Arterial Hypertension Related to PARP Inhibitors

Completed
N/A
2336
Europe
olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
University Hospital, Caen
Cancer
05/21
09/22
MITO 34, NCT04617470: Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study

Recruiting
N/A
300
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, GlaxoSmithKline
Ovarian Cancer
01/22
01/22
ROMP, NCT04582552: The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Recruiting
N/A
60
RoW
PARP inhibitors, Lynparza, Zejula
Xiaoxiang Chen
Ovarian Cancer, Clinical Marker, PARP Inhibitor
05/22
11/23
REFIRM, NCT06086665: The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

Completed
N/A
850
RoW
Niraparib
Asan Medical Center, Samsung Medical Center, Seoul National University Hospital, Severance Hospital, Gangnam Severance Hospital, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital, Seoul St. Mary's Hospital, National Cancer Center, Korea, Pusan National University Yangsan Hospital, Inje University, Pusan National University Hospital
Epithelial Ovarian Cancer
10/22
10/22
NCT05734911: Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study

Completed
N/A
199
RoW
Niraparib
Zhongda Hospital
Ovarian Neoplasms
12/22
02/23
NCT05401214: Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing
N/A
Europe, RoW
Niraparib plus Abiraterone Acetate (Nira/AA) combination, Prednisone/Prednisolone
Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Cancer
 
 
NCT05749211: Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Not yet recruiting
N/A
59
NA
Huaier granule, Niraparib
Ruijin Hospital
Ovarian Cancer
12/23
12/25
NCT06037213: A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib

Recruiting
N/A
500
RoW
Peking Union Medical College Hospital
Ovarian Cancer
12/23
01/24
MONITOR-UK, NCT04295577: Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

Recruiting
N/A
350
Europe
Niraparib
Royal Marsden NHS Foundation Trust
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
02/24
02/24
 

Download Options